Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1880 - IMagyn050 / GOG3015 / ENGOT-ov39: A randomized, double-blind, phase III study of atezolizumab vs placebo combined with chemotherapy + bevacizumab in stage III-IV ovarian, fallopian tube & peritoneal cancers (OC)


09 Sep 2017


Poster display session


Kathleen Moore


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


K.N. Moore1, A. Okamoto2, F. Wu3, Y.G. Lin4, S. Pignata5

Author affiliations

  • 1 Department Of Obstetrics And Gynecology, University of Oklahoma Health Sciences Center, 73117 - Oklahoma City/US
  • 2 Ob/gyn, The Jikei University School of Medicine, Tokyo/JP
  • 3 Product Development Biometrics, Roche, Beijing/CN
  • 4 Product Development Oncology, Genentech, Inc., South San Francisco/US
  • 5 Urology And Gynecology, Istituto Nazionale Tumori "Fondazione G. Pascale" IRCCS, 80131 - Naples/IT


Abstract 1880


Despite surgical advances and initial responses to chemo, OC has the highest mortality among gynecologic cancers, underscoring the need to improve long-term outcomes over standard platinum/taxane regimens. OC is a VEGF-driven tumor, susceptible to both the anti-angiogenic and immunomodulatory activities of bev. The immune response may also be enhanced by blocking the PD-L1/PD-1 and PD-L1/B7.1 pathways with atezo (anti–PD-L1), further potentiating anti-cancer T-cell activity. Atezo has shown safe and durable clinical benefit as a mono- and combinatorial therapy in human cancers, including OC. Here we present the first study in OC assessing dual immunomodulation with bev + atezo with standard chemo.

Trial design

IMagyn050 (NCT03038100) will enroll ≈ 1300 newly diagnosed stage III-IV epithelial OC patients (pts) globally. Pts must have ECOG PS ≤ 2, evaluable tissue for PD-L1 testing (VENTANA SP142 assay) and will either have gross residual disease postoperatively (primary surgery group) or receive neoadjuvant (neo) therapy followed by surgery then adjuvant (adj) therapy (neo group). A concurrent phase (IV AUC6 carboplatin [Cb] + 175 mg/m2 paclitaxel [pac] + 15 mg/kg bev + 1200 mg atezo/PL × 6 cycles [C]) will be followed by maintenance bev + atezo/PL on 21-d C for a total of 22 C atezo/PL (Table), with pts treated until completion of maintenance therapy, toxicity or recurrence, whichever occurs first. The neo group will undergo neo therapy followed by interval surgery between C3-4 then adj therapy followed by maintenance bev + atezo/PL. Stratification factors are stage and/or residual disease, ECOG PS, PD-L1 status and treatment approach. Co-primary endpoints PFS and OS will be assessed in all and PD-L1−positive (≥ 1%) pts. Safety, efficacy, PROs and translational data will also be evaluated.Table:


Treatment Groups (1:1 randomization)ConcurrentMaintenance
Primary surgeryC1: Cb + pac + atezo/PL C2-6: Cb + pac + bev + atezo/PLC7 onward: bev + atezo/PL
NeoC1-2 and 5-6: Cb + pac + bev + atezo/PL C3-4: Cb + pac + atezo/PLC7 onward: bev + atezo/PL

Clinical trial identification


Legal entity responsible for the study

F. Hoffman-La Roche Ltd.


F. Hoffman-La Roche Ltd.


K.N. Moore: Serve on advisory boards for AstraZeneca, Advaxis, Clovis, Tesaro, Immunogen, Genentech/Roche, VBL Therapeutics; Serve on steering committees for Advaxis, Clovis And Immunogen. F. Wu: Roche employee. Y.G. Lin: Genentech‐Roche employee. S. Pignata: Honorarium by Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.